title: Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis.
abstract: BACKGROUND
  Relative to hemoglobin A(1c) (HbA(1c)), percentage of glycated albumin (GA%) more accurately reflects recent glycemic control in diabetic hemodialysis (HD) patients.
  
  
  METHODS
  To determine the accuracy of glycemic assays in a larger sample including patients on peritoneal dialysis (PD), HbA(1c) and GA% were measured in 519 diabetic subjects: 55 on PD, 415 on HD, and 49 non-nephropathy controls.
  
  
  RESULTS
  Mean +/- SD serum glucose levels were higher in HD and PD patients relative to non-nephropathy controls (HD 169.7 +/- 62 mg/dL, PD 168.6 +/- 66 mg/dL, controls 146.1 +/- 66 mg/dL; p = 0.03 HD vs controls, p = 0.13 PD vs controls). GA% was also higher in HD and PD patients (HD 20.6% +/- 8.0%, PD 19.0% +/- 5.7%, controls 15.7% +/- 7.7%; p < 0.02 HD vs controls and PD vs controls). HbA(1c) was paradoxically lower in dialysis patients (HD 6.78% +/- 1.6%, PD 6.87% +/- 1.4%, controls 7.3% +/- 1.4%; p = 0.03 HD vs controls, p = 0.12 PD vs controls). The serum glucose/HbA(1c) ratio differed significantly between dialysis patients and controls (p < 0.0001 HD vs controls, p = 0.002 PD vs controls), while serum glucose/GA% ratio was similar across groups (p = 0.96 HD vs controls, p = 0.64 PD vs controls). In best-fit multivariate models with HbA(1c) or GA% as outcome variable, dialysis status was a significant predictor of HbA(1c) but not GA%.
  
  
  CONCLUSIONS
  The relationship between HbA(1c) and GA% differs in diabetic patients with end-stage renal disease who perform either PD or HD compared to those without nephropathy. HbA(1c) significantly underestimates glycemic control in peritoneal and hemodialysis patients relative to GA%.
authors.affiliation: Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1053, USA. bfreedma@wfubmc.edu
authors.forename: Barry I
authors.initials: BI
authors.lastname: Freedman
authors.forename: Rajeev N
authors.initials: RN
authors.lastname: Shenoy
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Planer
authors.forename: Kimberly D
authors.initials: KD
authors.lastname: Clay
authors.forename: Zak K
authors.initials: ZK
authors.lastname: Shihabi
authors.forename: John M
authors.initials: JM
authors.lastname: Burkart
authors.forename: Cesar Y
authors.initials: CY
authors.lastname: Cardona
authors.forename: Lilian
authors.initials: L
authors.lastname: Andries
authors.forename: Todd P
authors.initials: TP
authors.lastname: Peacock
authors.forename: Hernan
authors.initials: H
authors.lastname: Sabio
authors.forename: Joyce R
authors.initials: JR
authors.lastname: Byers
authors.forename: Gregory B
authors.initials: GB
authors.lastname: Russell
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Bleyer
mesh_terms: D048909:Diabetes Complications / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D017127:Glycation End Products, Advanced; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D006435:Renal Dialysis; D012709:Serum Albumin / Q000032:analysis*; D000093423:Glycated Serum Albumin
chemical_list: D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D000093423:Glycated Serum Albumin; C517652:hemoglobin A1c protein, human